Genetic testing of tumor is recommended for colorectal cancer patients

August 5, 2014, American Gastroenterological Association

Of the 143,000 patients diagnosed with colorectal cancer annually in the U.S., up to 25 percent have a familial risk of colorectal cancer. A new guideline from the U.S. Multi-Society Task Force on Colorectal Cancer recommends genetic testing of tumors for all newly diagnosed colorectal cancer patients. The task force makes specific surveillance and management recommendations for those affected by a genetic condition called Lynch syndrome, the most common cause of inherited colorectal cancer, accounting for approximately 3 percent, or more than 4,000, of the newly diagnosed cases in the U.S. each year.

Universal Tumor Testing

Universal genetic testing of the tumors for evidence of mismatch repair (MMR) deficiency of newly diagnosed patients is recommended for several reasons:

1. Use of clinical criteria and prediction models to identify patients with Lynch syndrome have less than optimal sensitivity and specificity.

2. It has been shown to be cost effective for the diagnosis of Lynch syndrome.

3. It has greater sensitivity for identification of Lynch syndrome compared with other strategies, including Bethesda guidelines, or a selective tumor testing strategy.

Genetic Counseling and Confirmatory Germline Genetic Testing

Individuals whose tumor shows evidence of MMR deficiency, have a known MMR gene mutation in the family, who meet clinical criteria for Lynch syndrome, or who have a personal risk of greater than or equal to 5 percent chance of Lynch syndrome based on prediction models should undergo a genetic evaluation for Lynch syndrome. Germline has the following advantages:

1. It can confirm a diagnosis of Lynch syndrome in the patient.

2. It can determine the status of at-risk family members in families in which disease mutation has been found.

3. It can direct the management of affected and unaffected individuals.

Management of Lynch Syndrome

Patients with Lynch syndrome are at an increased risk of developing colorectal , as well as cancers outside of the colon. The U.S. Multi-Society Task Force on Colorectal Cancer recommends that annual history, physical examination, and patient and family education regarding the risk of cancer should start between the ages of 20 and 25 years. In addition, the following recommendations are made for patients with or at risk of Lynch syndrome:

  • Colorectal cancer
    • Colonoscopy screening every one to two years beginning at ages 20 to 25, or two to five years younger than the youngest age of CRC diagnosis in the family, if the diagnosis was before the age of 25.

  • Endometrial cancer
    • Conduct pelvic exam screening and endometrial sampling annually starting between the ages of 30 and 35.

  • Ovarian cancer
    • Start annual transvaginal ultrasound screening at ages 30 to 35.
    • Hysterectomy and bilaterial salpingo-oophorectomy is recommended for women with Lynch syndrome at age 40 or after childbearing is complete.

  • Gastric cancer
    • Screen via endoscopy with gastric biopsy beginning at ages 30 to 35. Continue every two to three years based on patient risk factors.

  • Urinary cancer
    • Conduct annual urinalysis starting at ages 30 to 35.

Routine screening of the small intestine, pancreas, prostate and breasts are not recommended.

Treatment

There are two treatments recommended for patients affected with Lynch syndrome:

1. Removal of the large intestine: Colectomy with ileorectal anastomosis, which removes the large intestine and attaches the small intestine to the rectum, is the primary treatment for patients affected by Lynch syndrome who have or precancerous colon polyps that cannot be removed by colonoscopy. Less extensive surgery can be considered for patients older than 60 to 65 years of age.

2. Aspirin therapy: There is growing evidence that the use of aspirin is beneficial in preventing cancer in Lynch syndrome patients. While the evidence is not conclusive, treatment of an individual patient with aspirin is a consideration after discussing patient-specific risks, benefits and uncertainties of treatment.

In the U.S., colorectal cancer is a major health problem—it is the second leading cause of cancer death, causing nearly 51,000 deaths each year. Environmental causes and inheritance play varying roles in different patients with colorectal cancer. About 20 to 30 percent of colorectal cancer appear to have a and a minority has a genetic mutation that contributed to the development of the disease.

The U.S. Multi-Society Task Force on Colorectal Cancer is composed of gastroenterology specialists with a special interest in colorectal cancer, representing the American Gastroenterological Association, the American College of Gastroenterology and the American Society for Gastrointestinal Endoscopy. Experts on Lynch syndrome from academia and private practice were invited authors of this guideline. Representatives of the Collaborative Group of the Americans on Inherited Colorectal Cancers and the American Society of Colon and Rectal Surgeons also reviewed the manuscript.

The consensus statement, "Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer," is published in Gastroenterology, the official journal of the AGA Institute; American Journal of Gastroenterology, the official journal of ACG; Diseases of the Colon & Rectum, the official journal of ASCRS; and GIE: Gastrointestinal Endoscopy, the official journal of ASGE.

Explore further: Evidence mounts for endometrial cancer tumor testing to identify women with Lynch syndrome

Related Stories

Evidence mounts for endometrial cancer tumor testing to identify women with Lynch syndrome

December 11, 2013
A recent article by Norris Cotton Cancer Center researchers published in the January 2014 issue of the journal Clinical Chemistry reviews the scientific evidence that warrants screening all endometrial cancers for Lynch syndrome. ...

Researchers develop clinical screening program for no.1 genetic cause of colon cancer

February 14, 2013
(Medical Xpress)—Cleveland Clinic researchers have found that colorectal cancer outcomes could be improved with regular genetic screening for Lynch syndrome, the most common hereditary, adult-onset cause of colorectal cancer, ...

Snack attack: Eating unhealthy snack foods may affect cancer risk in patients with Lynch syndrome

December 17, 2012
A new analysis has found that loading up on snack foods may increase cancer risk in individuals with an inborn susceptibility to colorectal and other cancers. Published early online in CANCER, a peer-reviewed journal of the ...

Study revises colorectal cancer risk down and other cancer risks up for women with Lynch Syndrome

February 26, 2013
Lynch Syndrome is a heritable genetic mutation that causes colorectal, endometrial and other cancers. A cooperative study that included the University of Colorado Cancer Center, published in this month's issue of the Journal ...

Prostate cancer risk rises in men with inherited genetic condition

April 1, 2013
Men with an inherited genetic condition called Lynch syndrome face a higher lifetime risk of developing prostate cancer and appear to develop the disease at an earlier age, according to a new study led by researchers at the ...

New Mayo Clinic test targets Lynch syndrome, a risk factor for colon cancer

May 18, 2011
Mayo Clinic has developed a screening procedure that could dramatically increase testing for Lynch syndrome, a hereditary genetic disorder that raises cancer risk, particularly for colorectal cancer. An estimated 3 percent ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.